Drug Profile


Alternative Names: Anti-LT alpha; MLTA 3698 A; PRO 283698; RG 7416

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Lymphotoxin alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 23 May 2013 Genetech completes a phase II trial in Rheumatoid Arthritis in the US, Bulgaria, Chile, Germany, Hungary, Mexico, Spain, Peru, Poland and Romania (NCT01225393)
  • 30 Jan 2013 Discontinued - Phase-I for Rheumatoid arthritis in Hungary (IV)
  • 30 Jan 2013 Discontinued - Phase-I for Rheumatoid arthritis in Hungary (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top